InSyBio at Open Coffee Athens CI

InSyBio at Open Coffee Athens CI

• 1.
  A disruptor toPrecision Medicine & Nutrition through biomarkers’ discovery Labros Digonis, Co-Founder & CEO Dr. Konstantinos Theofilatos, Co-Founder and CTO
• 2.
  If severely ill,what are the chances he survives if his life depends on drug under trial? 52% of clinical trials fail due to drug efficacy and wrong targeting of patients! Source: IMS 6.7% of hospitalized patients have adverse drug reaction (ADR) and 0.32% die Source: FDA 2
• 3.
  Drug development isa long, expensive process Source: The Tribune Average $2.9B and 8 years to get drug to market
• 4.
  The History ofWaiting and its deadly track record 4 Drug Indicated disease Clinical Delay Result Eloxatin Colorectal cancer 3 years 40,000 Americans died waiting Erbitux Colorectal and head and neck cancer 2 years 179,000 people died waiting Revlimid MDS, Multiple Myeloma, MCL 2.5 years 74,000 patients died without getting drug Tarceva Lung cancer, Pancreatic cancer 3 years 633,000 patients died waiting Tykerb Breast cancer 3 years 28,000 women died waiting Velcade Multiple Myeloma 1 year 2,600 patients died waiting
• 5.
  Drug efficacy resultsare negatively affected because people respond to treatments differently + + = = BiDil approved for use only in patients of African descent • Two medications combined. Indicated for cardiovascular disease, heart failure diabetes • Only a subgroup of people received a benefit during trials Example:
• 6.
  Molecular biomarkers canbe used to predict responses to drugs or food Molecular Biomarker Something that can be measured which points to the presence of a disease or differentiation in response to a treatment or drug Specific to: different -omics technologies Molecular Biomarker Example A combination of overexpressed genes, or mutations to diagnose tumors
• 7.
  Molecular biomarkers canbe used to predict responses to drugs or food Molecular Biomarker Something that can be measured which points to the presence of a disease or differentiation in response to a treatment or drug Specific to: different -omics technologies Benefits of Finding Biomarkers • Minimizes the risks for failed trials • Patient Stratification: Enables the optimal selection of participants to clinical trials • Interpretation of the cause of diseases • Allows precision medicine: provide the more suitable drug to each patient in a personalized manner. Molecular Biomarker Example A combination of overexpressed genes, or mutations to diagnose tumors
• 8.
  Biomarker discovery isa fragmented Data-driven process Biological Experiments Data Preprocessing & Visualization Meta-Analysis Biomarker extraction Diagnostic & Clinical Trials Applications • DNA & RNA sequences • Microarrays • NGS • Mass Spectrometry. • Proteins • Biological networks • Associated sequences, mRNA, non-coding RNA, SNPs) • Holistic/Systemic approach to Research & Clinical deduction • Integrated biomarkers of high confidence • Biological interpretation with affected pathways & side-effects prediction. • Diagnosis, prognosis • Drug Response/Toxicity prediction • Disease progression • Therapeutic response. Biomarker ID takes time, money and expertise
• 9.
  Biomarker discovery isa fragmented Data-driven process Biological Experiments Data Preprocessing & Visualization Meta-Analysis Biomarker extraction Diagnostic & Clinical Trials Applications • DNA & RNA sequences • Microarrays • NGS • Mass Spectrometry. • Proteins • Biological networks • Associated sequences, mRNA, non-coding RNA, SNPs) • Holistic/Systemic approach to Research & Clinical deduction • Integrated biomarkers of high confidence • Biological interpretation with affected pathways & side-effects prediction. • Diagnosis, prognosis • Drug Response/Toxicity prediction • Disease progression • Therapeutic response. Existing platforms are performing only part of the analysis
• 10.
  Biomarker discovery isa fragmented Data-driven process Biological Experiments Data Preprocessing & Visualization Meta-Analysis Biomarker extraction Diagnostic & Clinical Trials Applications • DNA & RNA sequences • Microarrays • NGS • Mass Spectrometry. • Proteins • Biological networks • Associated sequences, mRNA, non-coding RNA, SNPs) • Holistic/Systemic approach to Research & Clinical deduction • Integrated biomarkers of high confidence • Biological interpretation with affected pathways & side-effects prediction. • Diagnosis, prognosis • Drug Response/Toxicity prediction • Disease progression • Therapeutic response. InSyBio is first to integrate the process and extract prioritized and relevant biomarkers from raw data Public databases & knowledge InSyBio Suite is a proprietary, cloud platform for big biological data analysis
• 11.
  Biomarkers Disease Interpretation Cause of Disease Mechanism Genetic Mutations Diagnostictests Prognosis/Predispositions Novel Therapies Improved efficiency Personalized Medicine AI- Machine Learning Biological Experiments Clinical Trials Hospital EHR Research Institutes Pharma Disrupting Clinical trials and Drug discovery process A model approach to Precision Medicine & Nutrition through biomarkers’ discovery at a glance
• 12.
  Accurate, targeted, andhighly reproducible biomarkers with small sample size requirements 10 Case Studies Method Number of biomarkers Accuracy Early Stage Parkinson’s Diagnosis State-of-the-art Method 834 ~96% InSyBio solution 5 100% Ischemic Stroke Diagnosis State-of-the-art Method ~3000 <70% InSyBio solution 4 88% Glioblastoma Diagnosis State-of-the-art Method 24 90.01% InSyBio solution 13 94.45%
• 13.
  …extracted Fast andat a Low-cost thru a single user friendly platform decreasing thus the need for many validation experiments and outsourced bioinformatics analysis ~ 6 months ~ 1/6 of time $100,000 - $millions Time to extract biomarkers Relative Cost to extract biomarkers 1/8 cost Fast Cost Effective
• 14.
  Our innovation liesin 4 main areas One, end-to-end, integrated process for biomarker discovery Data (Vertical) Integration from many sources with patent-protected network-based approach Technology to locate 30% more common proteins in proteomics data Rifle Approach Fewer, relevant and accurate biomarkers
• 15.
  Our technology hasalready demonstrated ability to accelerate pharma & nutrition R&D tasks Nutrition Diet Selection/Effects of nutrition products in health and patients Pharma: Clinical Trials Discovery of candidate-biomarkers for effective patient recruitment R&D resources efficiency Shorten time-to-market Pharma: Pre-clinical Drug Design Faster and more reliable detection of drug targets Minimization of risk for side effects Diagnostic Companies and Labs Diagnostic, prognostic and therapeutic biomarker discovery Less candidate biomarkers, higher predictive accuracy More than 400 active users with applications in: • Parkinson’s • Alzheimer’s • Major Depression • Melanoma • Cancer radiotherapy
• 16.
  The incorporation ofInSyBio’s Technology in Clinical Trials can save thousands! • ~25,000 new clinical trials per year • Average success rate is being increased by 16% with the use of predictive biomarkers • 40% of those trials already try to use predictive biomarkers • InSyBio technology can allow the use of predictive biomarkers in the remaining 60% ending up with on average ~2400 more successful clinical trials and drugs to market annually 15 Sources: Clarivate Analytics Cortellis, Feb 2017; Quintiles IMS Institute, April 2017, BiomedTracker for Pharma Intelligence, Informa, Clinical Development Success Rates 2006-2015
• 17.
  The InSyBio team Efficient& forward-looking with strong business and scientific background Dr. Christos Alexakos COO Computer Engineer, MSc, PhD in Computer Science Labros Digonis CEO Entrepreneurial Manager, Naval Architect & Marine Engineer, MBA Dr. Konstantinos Theofilatos CTO, Technical Sales Mgr. Computer Engineer, MSc, PhD in Bioinformatics Christos Dimitrakopoulos R&D Mgr. Computer Engineer, MSc, PhD Candidate in Computational Biology Aigli Korfiati Product Development Mgr. Computer Engineer, MSc, PhD Candidate Dr. Seferina Mavroudi CSO Computer Engineer, MSc, PhD in Bioinformatics Prof. Georgios Georgiou University of Texas Prof. Nicholas Peppas University of Texas, Member of Chinese Academy Prof. Konstantinos Stathopoulos University of Patras Dr. Alexandros Georgakilas National Technical University of Athens Co – Founders Team Scientific Advisory Committee 13
• 18.
  Recent Publications andpatents • Theofilatos, K., Alexakos, C., Korfiati, A., Dimitrakopoulos, C. and Mavroudi, S., Theofilatos and Konstantinos, 2018. Generalized Computational Framework And System For Integrative Prediction Of Biomarkers. U.S. Patent Application 15/837,407. • Theofilatos, K., Dimitrakopoulos, C., Mavroudi, S., Korfiati, A. and Alexakos, C., InSyBio Ltd, 2017. Protein functional and sub-cellular annotation in a proteome. U.S. Patent Application 15/361,461. • J. Corthésy and K. Theofilatos, et al., An Adaptive Pipeline To Maximize Isobaric Tagging Data in Large-Scale MS-Based Proteomics, Journal of Proteome Research 2018 17 (6), 2165-2173, DOI: 10.1021/acs.jproteome.8b00110 • A. Korfiati, K. Theofilatos, C. Alexakos and S. Mavroudi, InSyBio ncRNASeq: An efficient tool for analyzing non-coding RNAs, EMBnet.journal, [S.l.], v. 23, p. e882, oct. 2017, DOI :https://doi.org/10.14806/ej.23.0.882. • C. Dimitrakopoulos, K. Theofilatos, et al. (2016) InSyBio BioNets: A new tool for analyzing biological networks and its application to biomarker discovery, EmbNet Journal, vol. 22, pp. e871, 2016, DOI: http://dx.doi.org/10.14806/ej.22.0.871. • C. Dimitrakopoulos, K. Theofilatos, A. Pegkas, S. Likothanassis, S. Mavroudi, Predicting overlapping protein complexes from weighted protein interaction graphs by gradually expanding dense neighborhoods, Artificial Intelligence in Medicine Journal, 2016, DOI: http://dx.doi.org/10.1016/j.artmed.2016.05.006 • Nikitaki, Zacharenia, et al. "Systemic mechanisms and effects of ionizing radiation: A new ‘old’ paradigm of how the bystanders and distant can become the players." Seminars in cancer biology. Academic Press, 2016, DOI: https://dx.doi.org/10.1016/j.semcancer.2016.02.002. • K. Theofilatos, S. Likothanassis, S. Mavroudi (2015) Quo vadis* Computational Analysis of PPI data Or Why the Future isn’t Here Yet, Frontiers in Genetics, vol. 6, pp. 289, DOI= https://dx.doi.org/10.3389/fgene.2015.00289 • Kleftogiannis, D., Theofilatos, K., Likothanassis, S., & Mavroudi, S. (2015). YamiPred: A novel evolutionary method for predicting pre-miRNAs and selecting relevant features. IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB), 12(5), 1183-1192. • Rapakoulia, T., Theofilatos, K., Kleftogiannis, D., Likothanasis, S., Tsakalidis, A., & Mavroudi, S. (2014). EnsembleGASVR: a novel ensemble method for classifying missense single nucleotide polymorphisms. Bioinformatics, 30(16), 2324-2333. • Theofilatos, K., Dimitrakopoulos, C., Likothanassis, S., Kleftogiannis, D., Moschopoulos, C., Alexakos, C., ... & Mavroudi, S. (2014). The Human Interactome Knowledge Base (HINT-KB): an integrative human protein interaction database enriched with predicted protein–protein interaction scores using a novel hybrid technique. Artificial Intelligence Review, 42(3), 427-443. 16
• 19.
  Insybio Biomarkers 22
• 20.
  Insybio Bionets 23
• 21.
  Insybio Interact 24
• 22.
  Find Us url: http://www.insybio.com demo:http://demo.insybio.com evaluation: http://evaluation.insybio.com Contact Us [email protected] Open Jobs [email protected]